Serum and urine apolipoprotien A1 (ApoA1) as biomarkers in bladder cancer

Abstract

Bladder cancer (BC) is the predominant malignant neoplasm in the urinary system and ranks as the tenth most prevalent malignant tumor worldwide. Compared with females, males displayed a four-fold more common incidence of bladder cancer. It mainly affects men. Bladder cancer is the fourth most prevalent neoplasm in males. The most important protein that makes up high density lipoprotein (HDL), ApoA-I apolipoprotein A1 is essential in regulating the right amount of cholesterol. Multiple inquiries have demonstrated that APOA1 plays a pivotal role in the progression, infiltration, and spread of tumors. Objectives. The objective of this study was to measure the level of urine to serum apolipoprotein A1 in patients suffering from bladder cancer and investigate the impact of variations to this nanotechnology on the development of the cancer. Material and methods. The study collected 45 blood and urine samples from individuals diagnosed with bladder cancer at Ghazi Hariri Hospital for Specialized Surgery. The samples included both males and females of various ages (61.47±11.28 years). Additionally, 45 blood and urine samples were collected from individuals without the disease. The samples were analyzed using an ELISA method to measure the levels of apolipoprotein A1 in the serum and urine of both groups, and the data collection period spanned from January 2023 to June 2023. Result. The average levels of serum and urine apolipoprotein A1 in the patients' group (14.18±2.62ng/ml, 20.04±4.67ng/ml) were significantly higher than the average levels in the control group (8.21±1.35, 8.94±1.74), with p-values of <0.001 and ≤0.001, respectively. The blood concentration of apolipoprotein A1 showed a significant positive moderate connection with the concentration of apolipoprotein A1 in urine (r=0.45, p<0.001). Conclusion. The mean and SD of serum apolipoprotein A1 in the patients group were higher than control group and urine apolipoprotein A1 in the patients group were higher than control group can be utilized as biomarkers for detecting bladder cancer. However, urine apolipoprotein A1 is a superior biomarker compared to serum apolipoprotein A1 due to its association with several other diseases.